PubRank

Trial to Evaluate the Effect of ALN-PCSSC Treatment on Low Density Lipoprotein Cholesterol (LDL-C) (ORION)

Clinical Trial ID NCT02597127

PubWeight™ 1.45‹?›

🔗 Visit the ClinicalTrials.gov page for NCT02597127

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature 2001 57.23
2 Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet 2004 42.12
3 Sequence variations in PCSK9, low LDL, and protection against coronary heart disease. N Engl J Med 2006 23.83
4 Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 2004 23.07
5 Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet 2010 18.09
6 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation 2013 16.52
7 Therapeutic silencing of an endogenous gene by systemic administration of modified siRNAs. Nature 2004 12.75
8 Mutations in PCSK9 cause autosomal dominant hypercholesterolemia. Nat Genet 2003 11.67
9 ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Eur Heart J 2011 10.52
10 Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysis. Lancet 2008 8.53
11 Effect of a monoclonal antibody to PCSK9 on LDL cholesterol. N Engl J Med 2012 8.24
12 The role of surface carbohydrates in the hepatic recognition and transport of circulating glycoproteins. Adv Enzymol Relat Areas Mol Biol 1974 7.83
13 RNAi-mediated gene silencing in non-human primates. Nature 2006 7.60
14 Potent and persistent in vivo anti-HBV activity of chemically modified siRNAs. Nat Biotechnol 2005 5.37
15 Safety and efficacy of RNAi therapy for transthyretin amyloidosis. N Engl J Med 2013 3.97
16 PCSK9: a convertase that coordinates LDL catabolism. J Lipid Res 2008 3.92
17 Molecular characterization of loss-of-function mutations in PCSK9 and identification of a compound heterozygote. Am J Hum Genet 2006 3.38
18 Design of noninflammatory synthetic siRNA mediating potent gene silencing in vivo. Mol Ther 2005 3.28
19 Atorvastatin with or without an antibody to PCSK9 in primary hypercholesterolemia. N Engl J Med 2012 3.15
20 First-in-humans trial of an RNA interference therapeutic targeting VEGF and KSP in cancer patients with liver involvement. Cancer Discov 2013 2.88
21 Low-density lipoprotein cholesterol-lowering effects of AMG 145, a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 serine protease in patients with heterozygous familial hypercholesterolemia: the Reduction of LDL-C with PCSK9 Inhibition in Heterozygous Familial Hypercholesterolemia Disorder (RUTHERFORD) randomized trial. Circulation 2012 2.37
22 Postexposure protection of guinea pigs against a lethal ebola virus challenge is conferred by RNA interference. J Infect Dis 2006 2.19
23 Results of the National Cholesterol Education (NCEP) Program Evaluation ProjecT Utilizing Novel E-Technology (NEPTUNE) II survey and implications for treatment under the recent NCEP Writing Group recommendations. Am J Cardiol 2005 2.11
24 Effectiveness of statin titration on low-density lipoprotein cholesterol goal attainment in patients at high risk of atherogenic events. Am J Cardiol 2003 2.06
25 Effect of a monoclonal antibody to PCSK9 on low-density lipoprotein cholesterol levels in statin-intolerant patients: the GAUSS randomized trial. JAMA 2012 1.99
26 The C679X mutation in PCSK9 is present and lowers blood cholesterol in a Southern African population. Atherosclerosis 2006 1.99
27 Effects of AMG 145 on low-density lipoprotein cholesterol levels: results from 2 randomized, double-blind, placebo-controlled, ascending-dose phase 1 studies in healthy volunteers and hypercholesterolemic subjects on statins. J Am Coll Cardiol 2012 1.88
28 Inclisiran in Patients at High Cardiovascular Risk with Elevated LDL Cholesterol. N Engl J Med 2017 1.45
29 The unique role of proprotein convertase subtilisin/kexin 9 in cholesterol homeostasis. J Intern Med 2009 0.99
30 Anti-PCSK9 therapies for the treatment of hypercholesterolemia. Expert Opin Biol Ther 2012 0.96
31 LDL-C goal attainment among patients newly diagnosed with coronary heart disease or diabetes in a commercial HMO. J Manag Care Pharm 2007 0.93
32 Loss of early gains in low-density lipoprotein cholesterol goal attainment among high-risk patients. J Clin Lipidol 2010 0.89
33 Effect of a monoclonal antibody to PCSK9 on LDL cholesterol. N Engl J Med 2012 0.87
34 Effect of a monoclonal antibody to PCSK9 on LDL cholesterol. N Engl J Med 2012 0.84
Next 100